An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

Slides:

Advertisements

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Advertisements

Primary Mucoepidermoid Carcinoma of the Esophagus

High-Risk Human Papillomavirus–Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis Robert A.A. van Boerdonk, MSc, Johannes.

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F

Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K

Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming.

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma Taylor M.

Electronic Updates for JTO Readers

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

An Unusual Presentation of Malignant Pleural Mesothelioma

Marleen J. ter Avest, BSc, Romane M. Schook, MD, Pieter E

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Pneumonectomy-Sparing NSAID Therapy for Pulmonary Inflammatory Myofibroblastic Tumor Sofia Ghani, MD, Arpita Desai, MD, Saraswati Pokharel, MD, Todd.

Esophageal Ultrasound-Controlled Fine Needle Aspiration for Staging of Mediastinal Lymph Nodes in Patients with Resectable Lung Cancer: Do We Always See.

Surgical Treatment of a Giant Symptomatic Cardiac Lipoma

Primary Mucoepidermoid Carcinoma of the Esophagus

High-Risk Human Papillomavirus–Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis Robert A.A. van Boerdonk, MSc, Johannes.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy Takehito Shukuya, MD, PhD, Sandipkumar Patel,

Role of Chromosome 3q Amplification in Lung Cancer

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

“The Best-Laid Plans … Often go Awry …”

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

Iris Metastasis in Small-Cell Lung Carcinoma

Esophagitis: A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Non– Small-Cell Lung Cancer Neeharika Srivastava, MD, Paul A. VanderLaan,

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Mitotic Inhibitors Journal of Thoracic Oncology

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Primary Lung Cancer Presenting with Gastrointestinal Tract Involvement: Clinicopathologic and Immunohistochemical Features in a Series of 18 Consecutive.

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

Phase I Study of Lenalidomide in Solid Tumors

A Nonresponding Small Cell Lung Carcinoma

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

European Lung Cancer Conference (ELCC) 2016 Organisation

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Neuroendocrine Cancer of the Lung: A Diagnostic Puzzle

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

A B3 Type-Thymoma in a 7-Year-Old Child with Myasthenia Gravis

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Journal of Thoracic Oncology

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke Ylstra, PhD, Mark A. van de Wiel, PhD, Paul P. Eijk, MSc, Marinus A. Paul, MD, PhD, Egbert F. Smit, Prof, MD, PhD, Pieter E. Postmus, Prof, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 8, Pages e3-e5 (August 2012) DOI: 10.1097/JTO.0b013e31825bcead Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Hematoxylin and eosin stain of biopsy from first (A) and second (B) SCLC are shown with CD56 immunohistochemical staining on first (C) and second (D) SCLC. SCLC, small-cell lung cancer. Journal of Thoracic Oncology 2012 7, e3-e5DOI: (10.1097/JTO.0b013e31825bcead) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Chromosomal aberrations as detected by array CGH for both SCLC biopsies are shown. On the y axis is the log2 tumor to normal ratio and on the x axis the chromosomal position in bp. Gray dots are individual array measurements (105K in total) and red lines, their segmented values. Gain and loss are positive and negative log2 ratio, respectively. All array data are available in the GEO database (GSE16575). SCLC, small-cell lung cancer. Journal of Thoracic Oncology 2012 7, e3-e5DOI: (10.1097/JTO.0b013e31825bcead) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions